Deep Vein Thrombosis Market Report 2026

Deep Vein Thrombosis Market Overview

• Deep Vein Thrombosis market size has reached to $1.09 billion in 2025 • Expected to grow to $1.37 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Rising Demand For Deep Vein Thrombosis (DVT) Treatment Drives Market Growth • Market Trend: Thinksono And Nyu Langone Health Partner To Advance Ai-Powered Ultrasound For Deep Vein Thrombosis Diagnosis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Deep Vein Thrombosis Market?

Deep vein thrombosis (DVT) refers to a serious medical condition that occurs when a blood clot forms in one or more of the deep veins in the body. The symptoms of DVT can include swelling, pain, and tenderness in the affected area, usually the leg. The main types of drugs used to treat deep vein thrombosis are anticoagulants, inferior vena cava filters, and others. Anticoagulants, also known as blood thinners, are medications that are used to prevent blood clots from forming in the blood vessels. It is treated by surgery, drugs, and others and various modes of administration are included, such as injectable, oral, and others. These are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by various end-users, including hospitals, homecare, specialty clinics, and others.

What Is The Deep Vein Thrombosis Market Growth Forecast?

The deep vein thrombosis market size is expected to see steady growth in the next few years. It will grow to $1.37 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advancement in novel anticoagulant therapies, increasing preference for oral over injectable treatments, expansion of homecare and remote monitoring, growth in preventive screening programs, improved access through online pharmacies. Major trends in the forecast period include growing adoption of direct oral anticoagulants, shift toward outpatient and home-based dvt management, increased focus on early diagnosis and risk stratification, rising use of minimally invasive interventional procedures, expansion of online and specialty pharmacy channels.

Global Deep Vein Thrombosis Market Segmentation

1) By Drug Class: Anticoagulants, Inferior Vena Cava Filters, Other Drug Class 2) By Treatment: Surgery, Drugs, Other Treatments 3) By Mode Of Administration: Injectable, Oral, Other Modes Of Action 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-users Subsegments: 1) By Anticoagulants: Direct Oral Anticoagulants (DOACs), Vitamin K Antagonists, Low Molecular Weight Heparins, Unfractionated Heparin 2) By Inferior Vena Cava Filters: Retrievable IVC Filters, Permanent IVC Filters, Advanced IVC Filter Systems 3) By Other Drug Class: Thrombolytics, Antiplatelet Agents, Fibrinolytics, Combination Therapy

What Is The Driver Of The Deep Vein Thrombosis Market?

The increasing number of individuals who require deep vein thrombosis (DVT) treatment is expected to propel the growth of the deep vein thrombosis market going forward. DVT treatment refers to treating patients with deep vein thrombosis using drugs such as anticoagulants and others that prevent the formation of new blood clots and existing blood clots from getting larger, alleviating the disease condition. The increase in the number of patients requiring DVT treatment indicates an increase in the prevalence of deep vein thrombosis that requires products for DVT diagnosis, prevention, and treatment. For instance, in February 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, an overall 900,000 people could be affected each year in the United States due to deep vein thrombosis, and between 60,000 and 100,000 Americans die each year from DVT or PE (pulmonary embolism). Therefore, the increasing number of individuals requiring deep vein thrombosis (DVT) treatment is driving the market.

Key Players In The Global Deep Vein Thrombosis Market

Major companies operating in the deep vein thrombosis market are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Shire Pharmaceuticals, AstraZeneca PLC, Endo International plc

Global Deep Vein Thrombosis Market Trends and Insights

Major companies operating in the deep vein thrombosis market are focused on adopting strategic partnerships to enable quick diagnosis of deep vein thrombosis (DVT) and maximize their profits in the market. Such collaborations reflect the growing interest in leveraging AI and machine learning to improve medical diagnostics, including the rapid and precise identification of DVT. For instance, in November 2023, ThinkSono Ltd., a UK-based ultrasound AI company to diagnose deep vein thrombosis, partnered with NYU Langone Health, a US-based academic medical center, to launch the first clinical trial of a new artificial intelligence (AI)-powered ultrasound software that enables more rapid and portable diagnosis of deep vein thrombosis (DVT). Through this partnership, the ThinkSono Guidance System technology utilizes the power of AI to potentially detect DVT more rapidly, precisely, and affordably compared to conventional techniques. In patients with and without DVT, researchers will use the ThinkSono Guidance System in addition to standard ultrasound scanning. To evaluate and confirm the ThinkSono system's accuracy, the two approaches' performances will be contrasted. As part of the school's practical research curriculum, medical students from the NYU Grossman School of Medicine will also assist in running the trial.

What Are Latest Mergers And Acquisitions In The Deep Vein Thrombosis Market?

In March 2024, Pfizer Inc., a US-based a biopharmaceutical company, partnerhsed with Bristol-Myers Squibb (BMS) to provide grant support for continuing professional education in the areas of anticoagulation in atrial fibrillation and venous thromboembolism. This partnership encourages organizations to apply for grants aimed at supporting independent education initiatives that improve the understanding of oral anticoagulant treatments for patients with atrial fibrillation and venous thromboembolism. Bristol-Myers Squibb company is a US-based pharmaceutical company.

Regional Insights

North America was the largest region in the deep vein thrombosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Deep Vein Thrombosis Market?

The deep vein thrombosis market includes revenues earned by entities by providing services related to treatment such as blood thinning medication, thrombolytic therapy, interventional radiology therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Deep Vein Thrombosis Market Report 2026?

The deep vein thrombosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the deep vein thrombosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.